EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical course of psoriasis patients that discontinued biologics during the COVID ‐19 pandemic

Filiz Topaloğlu Demir iD, Algün Polat Ekinci, Sema Aytekin, Zeynep Topkarcı, Melek Aslan Kayıran iD, Tuğba Özkök Akbulut iD, İlteriş Oğuz Topal, Sezgi Sarıkaya Solak, Asude Kara Polat, Ayşe Serap Karadağ

Journal of Cosmetic Dermatology · 2023

DOI: 10.1111/jocd.15638 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cosmetic Dermatology, 2023. Verfasst von Filiz Topaloğlu Demir und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Venereology, Faculty of Medicine, Istanbul Medipol University, Istanbul, Turkey. Hauptthemen laut MEDLINE: Biological Products, COVID-19, Psoriasis. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Since psoriasis is a chronic disease, it is not recommended to discontinue the treatment agents used. However, in real life, the treatment of psoriasis patients may be interrupted for various reasons. During the pandemic period, the treatment of many patients was also interrupted.

Objectives

To evaluate relapse and clinical worsening in psoriasis patients whose biological therapy was interrupted during the pandemic and reveal associated factors.

Methods

The study included patients aged ≥18 years, who were followed up with moderate and severe chronic psoriasis controlled by the last biological agent [Psoriasis Area Severity Index (PASI) 75 response achieved] but had to discontinue their treatment during the pandemic. The patients' demographic and clinical characteristics, clinical course after the discontinuation of these agents, presence of clinical worsening, and relapse were evaluated. Risk factors were analyzed with the logistic regression analysis.

Results

The study included 169 patients, with a mean age of 47.3 ± 14.5 (18–87) years. The mean biologics‐free time was 18.2 ± 12.3 (2–56) weeks. Clinical worsening was detected in 41.4% and relapse in 48.5% of the patients. The significant risk factors for clinical worsening and relapse in both univariate and multivariate analyses were alcohol use during the biologics‐free period, total time off biologics, and the presence of an additional triggering factor. The use of secukinumab and ustekinumab was found to be a protective factor against clinical worsening in multivariate analyses.

Conclusion

As the biologics‐free period is prolonged, the likelihood of clinical worsening and relapse increases, therefore, we do not recommend discontinuing biological agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biological ProductsCOVID-19PsoriasisHumansAdolescentAdultMiddle AgedPandemicsTreatment OutcomeSeverity of Illness IndexBiological FactorsChronic DiseaseDisease Progression

Stichwörter der Autor:innen

medical therapypsoriasistreatment

Substanzen

Biological ProductsBiological Factors

Autor:innen und Institutionen

  • Department of Dermatology and Venereology, Faculty of Medicine, Istanbul Medipol University, Istanbul, Turkey.
  • Department of Dermatology and Venereology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
  • Department of Dermatology and Venereology, Faculty of Medicine, Tekirdag Namik Kemal University, Tekirdag, Turkey.
  • Department of Dermatology and Venereology, Istanbul Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Health Sciences University, Istanbul, Turkey.
  • Department of Dermatology and Venereology, Goztepe Training and Research Hospital, Istanbul Medeniyet University, Istanbul, Turkey.
  • Department of Dermatology and Venereology, Haseki Training and Research Hospital, Health Sciences University, Istanbul, Turkey.

ORCID-Profile: Filiz Topaloğlu Demir, Melek Aslan Kayıran, Tuğba Özkök Akbulut

Zitieren

APA

Topaloğlu Demir, F., Polat Ekinci, A., Aytekin, S., Topkarcı, Z., Aslan Kayıran, M., Özkök Akbulut, T., Oğuz Topal, İ., Sarıkaya Solak, S., Kara Polat, A., & Karadağ, A. S. (2023). Clinical course of psoriasis patients that discontinued biologics during the COVID ‐19 pandemic. Journal of Cosmetic Dermatology. https://doi.org/10.1111/jocd.15638

Vancouver

Topaloğlu Demir F, Polat Ekinci A, Aytekin S, Topkarcı Z, Aslan Kayıran M, Özkök Akbulut T, et al. Clinical course of psoriasis patients that discontinued biologics during the COVID ‐19 pandemic. Journal of Cosmetic Dermatology. 2023. doi:10.1111/jocd.15638

BibTeX
@article{TopaloluDemir2023,
  author = {Topaloğlu Demir, Filiz and Polat Ekinci, Algün and Aytekin, Sema and Topkarcı, Zeynep and Aslan Kayıran, Melek and Özkök Akbulut, Tuğba and Oğuz Topal, İlteriş and Sarıkaya Solak, Sezgi and Kara Polat, Asude and Karadağ, Ayşe Serap},
  title = {Clinical course of psoriasis patients that discontinued biologics during the COVID ‐19 pandemic},
  journal = {Journal of Cosmetic Dermatology},
  year = {2023},
  doi = {10.1111/jocd.15638}
}
Kostenlos starten →